The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
Abstract
BACKGROUND: Chromosomal translocations leading to chimeric oncoproteins are important in leukemogenesis, but how they form is unclear. We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II. METHODS: We used long-range polymerase chain reaction and sequence analysis to characterize t(15;17) genomic breakpoints in therapy-related APL. To determine whether topoisomerase II was directly involved in mediating breaks of double-stranded DNA at the observed translocation breakpoints, we used a functional in vitro assay to examine topoisomerase II-mediated cleavage in the normal homologues of the PML and RARA breakpoints. RESULTS: Translocation breakpoints in APL that developed after exposure to mitoxantrone, a topoisomerase II poison, were tightly clustered in an 8-bp region within PML intron 6. In functional assays, this "hot spot" and the corresponding RARA breakpoints were common sites of mitoxantrone-induced cleavage by topoisomerase II. Etoposide and doxorubicin also induced cleavage by topoisomerase II at the translocation breakpoints in APL arising after exposure to these agents. Short, homologous sequences in PML and RARA suggested the occurrence of DNA repair by means of the nonhomologous end-joining pathway. CONCLUSIONS: Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Self-citationOrigins of chromosome translocations in childhood leukaemia
Greaves, M. F., & Wiemels, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1164 · Cited by 699
Self-citationSmith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
Fortune, J. M., & Osheroff, N. (2000) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(00)64006-0 · Cited by 366
Self-citationPedersen-Bjergaard, J., & Rowley, J. (1994) · Blood · doi:10.1182/blood.v83.10.2780.2780 · Cited by 343
Glaz, J., Naus, J., & Wallenstein, S. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3460-7 · Cited by 306
Chromosome translocations: dangerous liaisons revisited
Rowley, J. D. (2001) · Nature Reviews Cancer · doi:10.1038/35106108 · Cited by 274
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., & Nerlov, C. (2002) · Blood · doi:10.1182/blood.v99.6.1909 · Cited by 246
Therapy-Related Acute Promyelocytic Leukemia
Beaumont, M., Sanz, M., Carli, P. M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.072 · Cited by 215
Self-citationRowley, J. D., & Olney, H. J. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10040 · Cited by 195
Cited by
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106
“Indeed, the clinical use of topoisomerase II poisons in cancer chemotherapy has been associated with an increased incidence of leukemia [241, 242].”
BackgroundMechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationRaffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., & Longo, V. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708100105 · Cited by 587
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Human topoisomerases and their roles in genome stability and organization
Pommier, Y., Nussenzweig, A., Takeda, S., & Austin, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00452-3 · Cited by 464
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Self-citationTherapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Advances in Understanding Benzene Health Effects and Susceptibility
Smith, M. T. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103646 · Cited by 412
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
DNA topoisomerase II, genotoxicity, and cancer
McClendon, A. K., & Osheroff, N. (2007) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2007.06.009 · Cited by 406
Self-citationMcHale, C. M., Zhang, L., & Smith, M. T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr297 · Cited by 345
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3612 · Cited by 292
Mechanisms of therapy-related carcinogenesis
Allan, J. M., & Travis, L. B. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1749 · Cited by 277
Liu, Y.-Q., Wang, X.-L., He, D.-H., & Cheng, Y.-X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153402 · Cited by 259
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 253
Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.07.002 · Cited by 42
Metadata
- Authors
- Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J. L., Segal, M. R., Adès, L., Blair, I. A., Osheroff, N., Peniket, A. J., Lafage-Pochitaloff, M., Cross, N. C. P., Chomienne, C., Solomon, E., Fenaux, P., & Grimwade, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-04-14
- Volume
- 352
- Issue
- 15
- Pages
- 1529-1538
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2067578884
- Cited by
- 281
- References
- 32
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.